Risk factors of ischaemic heart disease and long-term outcome after coronary bypass surgery

Journal of Cardiovascular Surgery

Volumn 42, Issue 6, 2001, Pages 731-734

  Efthimiadis, A ^a   Lefkos, N ^a   Psirropoulos, D ^a   Papadopoulos, I ^a   Boudonas, G ^a   Lefkou, E ^a   Efthimiadis, I ^a   Tsapas, G ^a  

^a Aristotle University and Hippokration General Hospital   (Greece)

Author keywords

Antithrombin III; Coronary artery bypass; Fibrinogen; Lipoprotein(a); Myocardial ischemia; Plasminogen activator inhibitor 1; Plasminogen activators; Risk factors

Indexed keywords

ANTIANGINA PECTORIS AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR; FIBRINOGEN; FIBRINOLYTIC FACTOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DISEASE COURSE; DRUG USE; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; RISK FACTOR;

ADULT; ANTITHROMBIN III; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY BYPASS; FEMALE; FIBRINOGEN; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; SURVIVORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0035211332     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. The recognition and management of hyperlipidaemia in adults: A policy statement of the European Atherosclerosis Society
2. A new serum type system in man: The Lp system
3. Lipoprotein(a); new IHD risk factor
4. Vascular interactions of lipoprotein(a)
5. Fluctuation of the lipoprotein (a) and the other lipoids in young people with family history of ischaemic heart disease
6. Lp (a) and atherosclerosis
7. Fibrinogen as a major risk factor in cardiovascular disease
8. Fibrinogen and risk of cardiovascular disease. The Framingham Study
9. Straton lecture. Thrombosis and atherogenesis: Molecular connections
10. Smoking and cardiac events after venous coronary bypass surgery: A 15-year follow-up study
11. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency
12. High density lipoproteins and coronary heart disease
13. Cost of lipid-lowering statin drugs
14. Inhibition of lipoprotein(a) and low density lipoprotein on growth of mitogen-stimulated human umbilical vein endothelial cells
15. Endothelial cells and atherosclerosis: Lipoprotein metabolism, matrix interactions and monocyte recruiment
16. Plasminogen activator inhibitor in plasma: Risk factor for recurrent AMI
17. Interrelationship between coagulant activity and tissue-type plasminogen activator [t-PA] system in acute ischaemic heart disease. Possible role of the endothelium
18. Regulation of very-low-density lipoprotein receptor in hypertrophic rat heart
19. Lipoprotein(a) and fibrinogen in acute myocardial infarction and after coronary artery bypass grafting
20. Serum cholesterol blood pressure and mortality: Implications from a cohort of 361,662 men
21. Risk factors changes and mortality results. MRFIT Research Group
22. Patterns of coronary heart disease morbitity and mortality in the sexes: A 26-year follow-up of the Framingham population
23. The cardiological point of view on stroke mortality in Greece
24. Ischaemic heart disease mortality rate in Greece during the last fifty years. Reduction or aggravation of the disease's spread?
25. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framinghan Study
26. Second report of the experts pannel education and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
27. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study
28. Cholesterol lowering and the reduction of CHD incidence and total mortality: Results from a meta-analysis of randomized trials
29. Effect of simvastatin on coronary atheroma: The Multicenter Anti-Atheroma Study
30. Lipids lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease
31. Effects of lipid lowering by pravastatin on progression and Regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)
32. Prevention of restenosis after percutaneous transluminal angioplasty by reducing lipoprotein(a) levels with low-density lipoprotein apheresis. L-ART Group
33. Binding of tissue plasminogen activator to cultured human endothelial cells
34. Impaired fibrinolysis in coronary artery disease